CommercialCoverageMedium impact
Lymphangioma and Infantile Hemangioma (CPB 0817, reviewed 2025-12-03)
Aetna·Pediatrics, Dermatology, Plastic Surgery +2 more·Medical Policy
Effective date
Dec 3, 2025
We identified it
Aug 16, 2026
Summary
Aetna's updated Clinical Policy Bulletin 0817 (effective 2025-12-03) establishes medical necessity criteria and coverage guidelines for lymphangioma and infantile hemangioma treatments, including specific propranolol dosing protocols for inpatient initiation, approved surgical and therapeutic interventions, and designates certain treatments (atenolol, topical timolol, sirolimus, biomarker testing) as experimental/investigational. Billing teams must ensure claims include proper medical necessity documentation, use correct procedure codes, and deny coverage for experimental treatments.
Action Required
By December 3, 2025: (1) Billing team must update claim submission rules in billing software to require medical necessity documentation for all hemangioma/lymphangioma treatment claims using CPT codes 11400-11446, 17106-17111, 11900-11901, 77401-77402 and ICD-10 codes D18.00-D18.09, D18.1, Q82.5. (2) Configure system to automatically deny or route for manual review any claims for experimental treatments: atenolol, topical timolol (no specific CPT), sirolimus (J7520, J9331), and biomarker testing (C19MC microRNAs, VEGF). (3) Providers and clinical staff must document in patient records that treatment meets ONE of four criteria: (a) lesion compromises vital structures (nose, eyes, ears, lips, larynx), (b) associated with Kasabach-Merritt Syndrome, (c) symptomatic (bleeding, painful, ulcerated, infected, pedunculated), or (d) results in documented functional impairment. (4) For propranolol claims: Verify inpatient initiation is medically necessary per policy (corrected age ≤8 weeks, inadequate social support, or cardiovascular/airway/glucose co-morbidities) before reimbursing inpatient stay; deny inpatient claims lacking this justification. (5) Update encounter templates and prior authorization workflows to capture required clinical criteria. Failure to implement will result in claim denials for lack of medical necessity and potential overpayment recovery.